Literature DB >> 3187457

Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire.

C Ekdahl1, K Eberhardt, S I Andersson, B Svensson.   

Abstract

The validity and reliability under Swedish conditions of a translated and slightly modified version of the Stanford Health Assessment Questionnaire (HAQ), referred to here as the ADL questionnaire, was studied. Sixty-four patients with definite/classical rheumatoid arthritis (RA) participated in the major part of the investigation. In addition, inter-observer reliability was studied in the testing of 15 other patients with RA. The questionnaire was filled in by the patients twice (ADL Tests 1 and 2) with a one-week interval between. A physiotherapist or occupational therapist also assessed each of the patients on a sample of ADL functions (ADL Test 3). Joint mobility, grip-strength, pain, Ritchie index and ESR were likewise checked. Results indicated inter-observer reliability to be high for the ADL (r(S) = 0.98), for joint mobility (r(S) = 0.86), and for the Ritchie index (r(S) = 0.83). The test-retest reliability for the ADL questionnaire which the patients filled in (Tests 1 and 2) was high r(S) = 0.91. Results of the ADL questionnaires the patients completed were found to correlate fairly closely with the observations of the therapists, r(S) = 0.71. The validity of the scoring system was found to be sufficient, using Ward's cluster analysis for comparing the original HAQ scores with scores on all the questions included in the questionnaire. Thus, the translated and somewhat modified version of the ADL questionnaire studied here appears to possess a high degree of reliability and validity in assessing patients with RA.

Entities:  

Mesh:

Year:  1988        PMID: 3187457     DOI: 10.3109/03009748809098795

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  120 in total

1.  Differences in activity limitation, pain intensity, and global health in patients with rheumatoid arthritis in Sweden and the USA: a 5-year follow-up.

Authors:  M Björk; L Trupin; I Thyberg; P Katz; E Yelin
Journal:  Scand J Rheumatol       Date:  2011-09-21       Impact factor: 3.641

2.  Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.

Authors:  C Carli; A G C Ehlin; L Klareskog; S Lindblad; S M Montgomery
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

Review 3.  Evaluation of quality of life for diverse patient populations.

Authors:  K R Yabroff; B P Linas; K Schulman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Questionnaire to evaluate the effects of assistive devices and altered working methods in women with rheumatoid arthritis.

Authors:  U Nordenskiöld; G Grimby; S Dahlin-Ivanoff
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

5.  Development of a functional scoring system for rheumatoid arthritis patients with cervical myelopathy.

Authors:  A T Casey; J M Bland; H A Crockard
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

6.  Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy.

Authors:  J Stümer; M H C Biermann; J Knopf; I Magorivska; A Kastbom; A Svärd; C Janko; R Bilyy; G Schett; C Sjöwall; M Herrmann; L E Muñoz
Journal:  Clin Exp Immunol       Date:  2017-06-13       Impact factor: 4.330

7.  Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

Authors:  P Geborek; M Crnkic; I F Petersson; T Saxne
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

8.  Muscle strength, endurance, and aerobic capacity in rheumatoid arthritis: a comparative study with healthy subjects.

Authors:  C Ekdahl; G Broman
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

9.  Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months.

Authors:  Inga-Lill Engvall; Birgitta Tengstrand; Kerstin Brismar; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2010-10-21       Impact factor: 5.156

10.  Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Ann-Charlotte Elkan; Niclas Håkansson; Johan Frostegård; Tommy Cederholm; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.